Brought to you by 
Novo Nordisk licenses growth factor to J&J and Chiron
04 Jun 2002
Executive Summary
Novo Nordisk AS has licensed Chiron and Johnson & Johnson the right to develop and market its platelet-derived growth factor (PDGF) to treat diabetic ulcers. Novo retains rights for other uses. Novo's ZymoGenetics subsidiary cloned the gene that codes for PDGF and demonstrated the role the protein plays in stimulating wound healing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo Nordisk licenses growth factor to J&J and Chiron
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice